These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27912175)

  • 1. Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
    Zhao D; Huang S; Qu M; Wang C; Liu Z; Li Z; Peng J; Liu K; Li Y; Ma X; Shu X
    Eur J Med Chem; 2017 Jan; 126():444-455. PubMed ID: 27912175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
    Liu H; Qu M; Xu L; Han X; Wang C; Shu X; Yao J; Liu K; Peng J; Li Y; Ma X
    Eur J Med Chem; 2017 Jul; 135():60-69. PubMed ID: 28432946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
    Ge Y; Yang H; Wang C; Meng Q; Li L; Sun H; Zhen Y; Liu K; Li Y; Ma X
    Bioorg Med Chem; 2017 Jan; 25(2):765-772. PubMed ID: 27956037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Zheng N; Pan J; Hao Q; Li Y; Zhou W
    Bioorg Med Chem; 2018 May; 26(8):2165-2172. PubMed ID: 29567295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
    Zou Y; Xiao J; Tu Z; Zhang Y; Yao K; Luo M; Ding K; Zhang Y; Lai Y
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3052-3059. PubMed ID: 27210433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
    Wang C; Li S; Meng Q; Sun X; Li H; Shu X; Sun H; Liu K; Liu Z; Ma X
    Bioorg Med Chem; 2018 Aug; 26(14):4179-4186. PubMed ID: 30006143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
    Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
    Zuo Y; Shi Y; Li X; Teng Y; Pan Z
    Sci Rep; 2015 Nov; 5():16136. PubMed ID: 26531233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
    Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
    Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
    Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Li X; Shi B; Teng Y; Cheng Y; Yang H; Li J; Wang L; He S; You Q; Xiang H
    Medchemcomm; 2019 Feb; 10(2):294-299. PubMed ID: 30881616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity.
    Qu M; Liu Z; Zhao D; Wang C; Zhang J; Tang Z; Liu K; Shu X; Yuan H; Ma X
    Bioorg Med Chem; 2017 Aug; 25(15):3989-3996. PubMed ID: 28576633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Zheng N; Hao Q; Lin K; Pan J; Li Y; Zhou W
    Bioorg Med Chem Lett; 2019 Jan; 29(2):225-229. PubMed ID: 30522954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.
    Wang B; Deng Y; Chen Y; Yu K; Wang A; Liang Q; Wang W; Chen C; Wu H; Hu C; Miao W; Hur W; Wang W; Hu Z; Weisberg EL; Wang J; Ren T; Wang Y; Gray NS; Liu Q; Liu J
    Eur J Med Chem; 2017 Sep; 137():545-557. PubMed ID: 28628824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
    Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
    Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
    Liu H; Wu B; Ge Y; Huang J; Song S; Wang C; Yao J; Liu K; Li Y; Li Y; Ma X
    Bioorg Med Chem; 2017 Dec; 25(24):6313-6321. PubMed ID: 29102081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Aug; 23(15):4344-4353. PubMed ID: 26169764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.